Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria

被引:33
|
作者
Mithwani, S
Aarons, L
Kokwaro, GO
Majid, O
Muchohi, S
Edwards, G
Mohamed, S
Marsh, K
Watkins, W
机构
[1] Wellcome Trust Res Labs, KEMRI Wellcome Trust Collaborat Res Programme, Nairobi, Kenya
[2] KEMRI Ctr Geog Med Res Coast Wellcome Trust Colla, Kilifi, Kenya
[3] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
[4] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
[5] Univ Liverpool, Liverpool Sch Trop Med, Div Mol & Biochem Parasitol, Liverpool L3 5QA, Merseyside, England
[6] Univ Khartoum, Fac Pharm, Dept Pharmaceut, Khartoum, Sudan
[7] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England
关键词
artemether; children; intramuscular injection; malaria; population pharmacokinetics;
D O I
10.1046/j.1365-2125.2003.01986.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To determine the population pharmacokinetics of artemether and dihydroartemisinin in African children with severe malaria and acidosis associated with respiratory distress following an intramuscular injection of artemether. Methods Following a single intramuscular (i.m.) injection of 3.2 mg kg(-1) artemether, blood samples were withdrawn at various times over 24 h after the dose. Plasma was assayed for artemether and dihydroartemisinin by gas chromatography-mass spectrometry. The software program NONMEM was used to fit the concentration-time data and investigate the influence of a range of clinical characteristics (respiratory distress and metabolic acidosis, demographic features and disease) on the pharmacokinetics of artemether and dihydroartemisinin. Results A total of 100 children with a median age of 36.4 (range 5-108) months were recruited into the study and data from 90 of these children (30 with respiratory distress and 60 with no respiratory distress) were used in the population pharmacokinetic analysis. The best model to describe the disposition of artemether was a one-compartment model with first-order absorption and elimination. The population estimate of clearance (clearance/bioavailability, CL/F) was 14.3 l h(-1) with 53% intersubject variability and that of the terminal half-life was 18.5 h. If it was assumed that artemisin displays 'flip-flop' kinetics, the elimination half-life was estimated to be 21 min and the corresponding volume of distribution was 8.44 l, with an intersubject variability of 104%. None of the covariates could be identified as having any influence on the disposition of artemether. The disposition of dihydroartemisinin was fitted separately using a one-compartment linear model in which the volume of distribution was fixed to the same value as that of artemether. Assuming that artemether is completely converted to dihydroartemisinin, the estimated value of CL/F for dihydroartemisinin was 93.5 l h(-1), with an intersubject variability of 90.2%. The clearance of dihydroartemisinin was formation rate limited. Conclusions Administration of a single 3.2 mg kg(-1) i.m. dose of artemether to African children with severe malaria and acidosis is characterized by variable absorption kinetics, probably related to drug formulation characteristics rather than to pathophysiological factors. Use of i.m. artemether in such children needs to be reconsidered.
引用
收藏
页码:146 / 152
页数:7
相关论文
共 50 条
  • [31] COMPARISON OF ARTEMETHER AND CHLOROQUINE FOR SEVERE MALARIA IN GAMBIAN CHILDREN
    WHITE, NJ
    WALLER, D
    CRAWLEY, J
    NOSTEN, F
    CHAPMAN, D
    BREWSTER, D
    GREENWOOD, BM
    LANCET, 1992, 339 (8789): : 317 - 321
  • [32] Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea
    Karunajeewa, HA
    Reeder, J
    Lorry, K
    Dabod, E
    Hamzah, J
    Page-Sharp, M
    Chiswell, GM
    Ilett, KF
    Davis, TME
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) : 968 - 974
  • [33] ARTEMETHER IN MODERATELY SEVERE AND CEREBRAL MALARIA IN NIGERIAN CHILDREN
    SALAKO, LA
    WALKER, O
    SOWUNMI, A
    OMOKHODION, SJ
    ADIO, R
    ODUOLA, AMJ
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1994, 88 : 13 - 15
  • [34] Population pharmacokinetics of intramuscular quinine in children with severe malaria
    Krishna, S
    Nagaraja, NV
    Planche, T
    Agbenyega, T
    Bedo-Addo, G
    Ansong, D
    Owusu-Ofori, A
    Shroads, AL
    Henderson, G
    Hutson, A
    Derendorf, H
    Stacpoole, PW
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1803 - 1809
  • [35] A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria
    Hien, TT
    Day, NPJ
    Phu, NH
    Mai, NTH
    Chau, TTH
    Loc, PP
    Sinh, DX
    Chuong, LV
    Vinh, H
    Waller, D
    Peto, TEA
    White, NJ
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02): : 76 - 83
  • [36] Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®)
    Tiono, Alfred B.
    Tinto, Halidou
    Alao, Maroufou J.
    Meremikwu, Martin
    Tshefu, Antoinette
    Ogutu, Bernhards
    Ouedraogo, Alphonse
    Lingani, Moussa
    Cousin, Marc
    Lefevre, Gilbert
    Jain, Jay Prakash
    Duparc, Stephan
    Hamed, Kamal
    MALARIA JOURNAL, 2015, 14
  • [37] Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®)
    Alfred B Tiono
    Halidou Tinto
    Maroufou J Alao
    Martin Meremikwu
    Antoinette Tshefu
    Bernhards Ogutu
    Alphonse Ouedraogo
    Moussa Lingani
    Marc Cousin
    Gilbert Lefèvre
    Jay Prakash Jain
    Stephan Duparc
    Kamal Hamed
    Malaria Journal, 14
  • [38] Population Pharmacokinetics of Lumefantrine in Pregnant Women Treated with Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria
    Tarning, Joel
    McGready, Rose
    Lindegardh, Niklas
    Ashley, Elizabeth A.
    Pimanpanarak, Mupawjay
    Kamanikom, Benjamas
    Annerberg, Anna
    Day, Nicholas P. J.
    Stepniewska, Kasia
    Singhasivanon, Pratap
    White, Nicholas J.
    Nosten, Francois
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) : 3837 - 3846
  • [39] Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Falciparum Malaria: A Longitudinal, Randomized Trial in Young Ugandan Children
    Arinaitwe, Emmanuel
    Sandison, Taylor G.
    Wanzira, Humphrey
    Kakuru, Abel
    Homsy, Jaco
    Kalamya, Julius
    Kamya, Moses R.
    Vora, Neil
    Greenhouse, Bryan
    Rosenthal, Philip J.
    Tappero, Jordan
    Dorsey, Grant
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (11) : 1629 - 1637
  • [40] High therapeutic efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Somalia
    Marian Warsame
    Abdillahi Mohamed Hassan
    Abdikarim Hussein Hassan
    Ali Mohamed Jibril
    Nimol Khim
    Abdulkadir Mohamed Arale
    Ahamed Hassan Gomey
    Zainab Said Nur
    Said Mohamed Osman
    Marian Said Mohamed
    Ali Abdulrahman
    Fahmi Essa Yusuf
    Jamal Ghilan Hefzullah Amran
    Benoit Witkowski
    Pascal Ringwald
    Malaria Journal, 18